C: Use with caution if Advantages outweigh pitfalls. Animal scientific tests demonstrate possibility and human experiments not available or neither animal nor human research completed.

pentobarbital will reduce the level or outcome of bexarotene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.

pentobarbital will lessen the extent or result of theophylline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.

pentobarbital will minimize the extent or effect of finasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unidentified.

pentobarbital will reduce the level or impact of fosphenytoin by impacting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Check.

pentobarbital will reduce the level or outcome of fentanyl intranasal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a minimize in fentanyl plasma concentrations, deficiency of efficacy or, potentially, advancement of a withdrawal syndrome in a very individual who's got designed physical dependence to fentanyl.

CYP3A4 inducers may well increase the formation on the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Carefully monitor sufferers getting ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment.

pentobarbital will reduce the extent or outcome of methylprednisolone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use here Caution/Monitor.

In the event the buprenorphine dose is insufficient and the CYP3A4 inducer can not be reduced or discontinued, transition the patient back to a buprenorphine formulation that permits dose changes.

With therapeutic doses of TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.

pentobarbital will lessen the level or impact of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unfamiliar.

pentobarbital will minimize the level or effect of atorvastatin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.

pentobarbital will lessen the extent or outcome of lefamulin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Prevent coadministration of lefamulin with robust or average CYP3A inducers Except the benefit outweighs dangers. Check for diminished efficacy.

pentobarbital will reduce the level or influence of fostemsavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.